About P2Y purinoceptor 13
P2Y purinoceptor 13 (P2RY13) is a protein
from Homo sapiens identified by UniProt accession
Q9BPV8, 354 residues long.
MolForge cross-references it against 0 known binders and
138 disease associations.
Target properties
| Protein name | P2Y purinoceptor 13 |
|---|
| UniProt accession | Q9BPV8 |
|---|
| Gene | P2RY13 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 354 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (3)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (138)
Diseases linked to this target (Open Targets).
- leukocyte count · score 0.28
- lymphocyte count · score 0.26
- glioblastoma multiforme · score 0.24
- ovarian cancer · score 0.23
- myeloid white cell count · score 0.21
- neutrophil count · score 0.20
- platelet-to-lymphocyte ratio · score 0.14
- monocyte count · score 0.14
- cutaneous melanoma · score 0.13
- breast adenocarcinoma · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9BPV8-F1 | alphafold | PREDICTED | 83.05 | — |
Amino-acid sequence (354 residues)
MTAAIRRQRE LSILPKVTLE AMNTTVMQGF NRSERCPRDT RIVQLVFPAL YTVVFLTGIL LNTLALWVFV HIPSSSTFII YLKNTLVADL IMTLMLPFKI LSDSHLAPWQ LRAFVCRFSS VIFYETMYVG IVLLGLIAFD RFLKIIRPLR NIFLKKPVFA KTVSIFIWFF LFFISLPNTI LSNKEATPSS VKKCASLKGP LGLKWHQMVN NICQFIFWTV FILMLVFYVV IAKKVYDSYR KSKSKDRKNN KKLEGKVFVV VAVFFVCFAP FHFARVPYTH SQTNNKTDCR LQNQLFIAKE TTLFLAATNI CMDPLIYIFL CKKFTEKLPC MQGRKTTASS QENHSSQTDN ITLG
Explore P2Y purinoceptor 13 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets